Premium Nahrungsergänzungsmittel | artgerecht

Aldosterone Antagonist – Effects, Uses and Side Effects

Aldosterone antagonists are medications that block the effects of the hormone aldosterone. They are used in heart failure, high blood pressure, and certain kidney conditions.

Regular tips about health Regular tips about health

Things worth knowing about "Aldosterone Antagonist"

Aldosterone antagonists are medications that block the effects of the hormone aldosterone. They are used in heart failure, high blood pressure, and certain kidney conditions.

What Is an Aldosterone Antagonist?

An aldosterone antagonist is a drug that inhibits the action of the naturally occurring hormone aldosterone at the mineralocorticoid receptor. Aldosterone is a steroid hormone produced in the adrenal cortex that plays a central role in regulating fluid and electrolyte balance – particularly the control of sodium and potassium levels in the blood. Aldosterone antagonists are also referred to as mineralocorticoid receptor antagonists (MRAs).

Mechanism of Action

Under normal circumstances, aldosterone binds to specific receptors in the kidneys (in the distal tubule and collecting duct), promoting sodium reabsorption and potassium excretion. This leads to water retention and, consequently, an increase in blood pressure.

Aldosterone antagonists competitively block these receptors – they occupy the same receptor as aldosterone but do not trigger its effects. The result is:

Increased sodium excretion via the kidneys (natriuretic effect)
Reduced potassium loss (potassium-sparing effect)
Lowering of blood pressure through reduced fluid volume in the body
Reduction of fibrosis and structural remodeling in the heart and blood vessels

Indications – When Are Aldosterone Antagonists Used?

Aldosterone antagonists are prescribed for a range of conditions:

Heart failure: In chronic heart failure, aldosterone antagonists improve prognosis by inhibiting cardiac remodeling and reducing mortality.
High blood pressure (arterial hypertension): Especially in treatment-resistant hypertension and primary hyperaldosteronism.
Primary hyperaldosteronism (Conn syndrome): A condition with excessive aldosterone production, where aldosterone antagonists neutralize the excess hormone.
Liver cirrhosis with ascites: Used to manage fluid accumulation in the abdominal cavity.
Nephrotic syndrome: Supportive therapy in certain kidney diseases involving significant protein loss in the urine.

Key Active Substances

The most well-known aldosterone antagonists include:

Spironolactone: The classic, non-selective mineralocorticoid receptor antagonist. However, it also acts on androgen and progesterone receptors, which can lead to hormonal side effects.
Eplerenone: A more selective mineralocorticoid receptor antagonist with a lower risk of hormonal side effects.
Finerenone: A newer, non-steroidal mineralocorticoid receptor antagonist used in chronic kidney disease associated with type 2 diabetes.

Dosage

The dosage of aldosterone antagonists depends on the underlying condition, kidney function, and the potassium level of the patient. Treatment is usually started at a low dose and adjusted gradually. Regular monitoring of kidney values and potassium levels is essential throughout therapy.

Side Effects

The most common side effects include:

Hyperkalemia: Elevated potassium levels in the blood – potentially dangerous for heart rhythm
Worsening of kidney function
Gynecomastia and breast tenderness (especially with spironolactone, due to its anti-androgenic effects)
Menstrual irregularities in women (with spironolactone)
Dizziness and low blood pressure
Gastrointestinal complaints

Contraindications

Aldosterone antagonists should not be used in cases of:

Severe renal insufficiency (risk of hyperkalemia)
Pre-existing hyperkalemia
Concurrent use of other potassium-raising medications without careful monitoring
Pregnancy (particularly spironolactone)

References

Ponikowski P et al. – 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016.
Funder JW et al. – The Management of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2016.
Bakris GL et al. – Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2020.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.